Immuneed will be attending the European Antibody Congress, one of the most important gatherings of senior health and biologic professionals. This congress is a part of the Festival of Biologics is a prime opportunity to network with the event’s 1,500+ attendees, hear from more than 350 speakers, and explore what’s new in the Biologics industry. …
Are you forgetting something in preclinical trials?
Complement activation is a risk – even if the classical pathway is blocked. Preclinical testing is vital to ensure the safety of clinical trials. So why is a key aspect of the body’s immune system almost systematically overlooked in preclinical assays? The complement system comprises upwards of 40 blood proteins synthesized by the liver. When …
Immuneed and HepaPredict signs collaboration agreement.
Uppsala 2019-10-02 Swedish biotech companies Immuneed AB and HepaPredict AB have entered into a collaboration agreement, the signing of which was announced today. The agreement combines our two companies’ scientific expertise, specialized laboratory platforms and unique methodological know-how, enabling us to offer even better custimized solutions for our customers. HepaPredict’s expertise in hepatotoxicity predictions and …
Immuneed AB and Danish biotech company ImmuMap ApS have entered into a collaboration agreement
Uppsala 2019-09-10 Swedish biotech company Immuneed AB and Danish biotech company ImmuMap ApS have entered into a collaboration agreement, the signing of which was announced today. The agreement combines our two companies’ scientific expertise, specialized laboratory platforms and unique methodological know-how, enabling us to offer even better tailored solutions for our customers. ImmuMap’s long-term mode-of-action …
Immuneed will be attending the Nordic Life Science Days 2019.
We’re looking forward to seeing new and familiar faces at the NLS days 2019. Drop by booth 54 to meet us and CTC Clinical Trials Consultants. Justyna Leja-Jarblad, COO of Immuneed, will give a talk on Sep 12. What? An innovative approach to prepare biopharmaceuticals for clinical development. The focus lies on preclinical safety assessment, …
Is your drug safe enough to enter the clinic?
Why choosing the right assay could make or break your first-in-man trial. In GLP toxicology studies, it’s an obvious choice to select a physiologically relevant animal model but when completing the safety assessment with in-vitro assays, researchers tend to get puzzled, often thinking that no results means “go”. The toxicity of monoclonal antibodies (mAbs) can …
Meet us in Stockholm, Sep 2 for a 3-hour seminar on how tailored preclinical testing adds value to early clinical trials.
What factors impact R&D efficiency and overall success for a small- or medium-sized biotech company? The Center for Medicine Research International (CMR) reported in its Pharmaceutical R&D Factbook 2014 an average success rate of 4.9 % from first toxicity dose to market approval. So what is the reason for the high attrition rate? The reasons are …
What’s lurking in that high background?
Uncover the potential safety risks of your drug candidate. Annually, the European pharma industry invests more than € 35 000 million to identify and develop new drugs, about 22% of which is spent on screening assays and toxicity testing. Of the 5000 compounds that enter pre-clinical testing, only five make it to the clinical phase. …
We’ll be at CIMT on May 21-23, 2019
We’ll be attending CIMT May 21-23, 2019. Meet up with our COO Justyna and Head of Research Erika at booth #10. Poster Abstract #56 on Tuesday, May 21 at 15.00-17.00. Presentation on Thursday, May 23 at 12.00: “Immunotoxicity assessment in a loop with circulating human blood”. See you there!
Seminar in Gothenburg: Accelerate your drug’s journey to the clinic.
Immuneed and CTC Clinical Trial Consultants will visit the major cities in Sweden for a joint seminar on how to manage risk and build value in early clinical development: “The Preclinical Human Model”. First out was Lund in March, and this seminar attracted many innovative biotech companies seeking to advance their current pipeline. Now we …
